These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32508184)

  • 1. 15-hydroxy-6
    Zhao Q; Lu L; Du G; Wang Z; Li X; Ju F
    Immunopharmacol Immunotoxicol; 2020 Aug; 42(4):358-365. PubMed ID: 32508184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 15-hydroxy-6α,12-epoxy-7β,10αH,11βH-spiroax-4-ene-12-one exerts anti-tumor effects against osteosarcoma through apoptosis induction.
    An TZ; Li Z; Ni CF; Zhou S; Yang C; Huang XQ; Li PC; Shen J
    Exp Ther Med; 2020 Apr; 19(4):2511-2518. PubMed ID: 32256729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies.
    Panni RZ; Herndon JM; Zuo C; Hegde S; Hogg GD; Knolhoff BL; Breden MA; Li X; Krisnawan VE; Khan SQ; Schwarz JK; Rogers BE; Fields RC; Hawkins WG; Gupta V; DeNardo DG
    Sci Transl Med; 2019 Jul; 11(499):. PubMed ID: 31270275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ.
    Cao L; Dai C; Qin R; Guo Y; Liu J
    Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):599-606. PubMed ID: 31691624
    [No Abstract]   [Full Text] [Related]  

  • 5. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
    Lin H; Wu Y; Chen J; Huang S; Wang Y
    Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
    Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
    Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.
    Schoonderwoerd MJA; Koops MFM; Angela RA; Koolmoes B; Toitou M; Paauwe M; Barnhoorn MC; Liu Y; Sier CFM; Hardwick JCH; Nixon AB; Theuer CP; Fransen MF; Hawinkels LJAC
    Clin Cancer Res; 2020 Jul; 26(14):3831-3842. PubMed ID: 32332012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian cancer modulates the immunosuppressive function of CD11b
    Udumula MP; Sakr S; Dar S; Alvero AB; Ali-Fehmi R; Abdulfatah E; Li J; Jiang J; Tang A; Buekers T; Morris R; Munkarah A; Giri S; Rattan R
    Mol Metab; 2021 Nov; 53():101272. PubMed ID: 34144215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8
    Tichet M; Wullschleger S; Chryplewicz A; Fournier N; Marcone R; Kauzlaric A; Homicsko K; Deak LC; Umaña P; Klein C; Hanahan D
    Immunity; 2023 Jan; 56(1):162-179.e6. PubMed ID: 36630914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
    Highfill SL; Cui Y; Giles AJ; Smith JP; Zhang H; Morse E; Kaplan RN; Mackall CL
    Sci Transl Med; 2014 May; 6(237):237ra67. PubMed ID: 24848257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
    Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
    Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.
    Rashidian M; LaFleur MW; Verschoor VL; Dongre A; Zhang Y; Nguyen TH; Kolifrath S; Aref AR; Lau CJ; Paweletz CP; Bu X; Freeman GJ; Barrasa MI; Weinberg RA; Sharpe AH; Ploegh HL
    Proc Natl Acad Sci U S A; 2019 Aug; 116(34):16971-16980. PubMed ID: 31375632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
    Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
    J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors.
    DeNardo DG; Galkin A; Dupont J; Zhou L; Bendell J
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.